Protocol Ledger

NCT06534437 · Phase II · RECRUITING

MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

Interventional Phase II clinical trial protocol NCT06534437 sponsored by Ryvu Therapeutics SA in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-12-05 Enrollment: 178 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06534437
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)178 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06534437
Protocol FieldVerified Registry Value
NCT IdentifierNCT06534437
Consolidated Lead SponsorRyvu Therapeutics SA
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment178 participants (ESTIMATED)
Registered Start Date2024-12-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06534437
Hospital Research SiteLocationSite Profile
Hospital Universitari Vall d'HebronBarcelona, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI